Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Neoplasms 5Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Solid Tumor 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Cancer 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × EC145 × Clear all
NCT01170650 2021-09-30

PROCEED

Endocyte

Phase 3 Terminated
441 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00507741 2015-01-07

Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Endocyte

Phase 2 Completed
49 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00722592 2015-01-07

PRECEDENT

Endocyte

Phase 2 Completed
162 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡